Sat, Jul 26, 2014, 4:07 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Pharmacyclics Inc. Message Board

  • jgmtruth jgmtruth Jun 27, 2013 10:01 AM Flag

    Again:Ibrutinib Promotes Remission in Chronic Lymphocytic Leukemia June 26, 2013

    (HealthDay News) – A new drug that targets interactions with the tumor microenvironment promotes remission in patients with relapsed chronic lymphocytic leukemia, according to a study published online June 19 in the New England Journal of Medicine.

    As part of a phase 1b-2 study, John C. Byrd, MD, from The Ohio State University in Columbus, and colleagues treated 85 patients with relapsed chronic lymphocytic leukemia with ibrutinib (PCI-32765) orally once a day, where 51 patients received 420mg and 34 received 840mg.

    The researchers found that both groups had the same overall response rate of 71%. An additional 20% of the 420-mg group and an additional 15% of the 840-mg group had a partial response with lymphocytosis. The responses were independent of clinical and genomic risk factors. The estimated rate of progression-free survival was 75% and the estimated rate of overall survival was 83% at 26 months. Toxicity was largely grade 1 or 2, including diarrhea, fatigue, and upper respiratory tract infection.

    "Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, including patients with high-risk genetic lesions," Byrd and colleagues conclude.

    The study was partially funded by Pharmacyclics and Janssen Biotech, the manufacturers of ibrutinib.

    Sentiment: Strong Buy

 
PCYC
104.82+0.32(+0.31%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.